Xihua Pharmaceutical signed a memorandum of cooperation with the Greater Bay Area International Clinical Trial Institute and the Greater Bay Area International Clinical Trial Center.
On July 28, 2026, the Greater Bay Area International Clinical Trials Institute, the Greater Bay Area International Clinical Trials Center, and Xihua Pharmaceutical Co., Ltd. signed a memorandum of cooperation today to establish a strategic cooperation framework, jointly promoting new drug R&D and conducting international multi-center clinical trials in Hong Kong and throughout the Greater Bay Area.
Under the "One Institute, One Center" framework, the Greater Bay Area International Clinical Trials Institute, established and wholly owned by the Hong Kong Special Administrative Region Government, and the Greater Bay Area International Clinical Trials Center, a branch established by the Shenzhen Academy of Medical Sciences, will join hands to promote the development of the clinical trial ecosystem in Hong Kong and the Greater Bay Area, fostering multi-center research collaboration within the region. Xihua Pharmaceutical is a biopharmaceutical company headquartered at the Hong Kong Science Park, focused on oncology and ophthalmology, currently in the late-stage clinical development phase. Through this cooperation, all parties hope to jointly explore opportunities to accelerate the R&D of innovative therapies, while further consolidating Hong Kong's position as a hub for international multi-center clinical trials.
Main Areas of Cooperation
Clinical Research and Trials: The three parties will discuss cooperation opportunities regarding areas of common interest, identification, design, and implementation of clinical trials. Under this framework, the Institute and the Center will strive to facilitate connections between Xihua Pharmaceutical and various clinical research centers in Hong Kong and the Greater Bay Area, supporting the overall development of the Greater Bay Area's clinical trial ecosystem. As the first biopharmaceutical company based in Hong Kong with late-stage clinical projects, Xihua Pharmaceutical plans to conduct multiple clinical studies in Hong Kong and the Greater Bay Area, including a Phase III international multi-center clinical trial targeting the enrollment of the first participant in the second half of 2026. Currently, preparatory work at multiple research centers in Hong Kong and the Greater Bay Area is underway, with the enrollment of the first participant expected to be completed in the short term.
Scientific Exchange and Event Organization: The Institute, the Center, and Xihua Pharmaceutical will explore co-hosting conferences, forums, and professional exchange activities to promote dialogue among clinicians, researchers, regulatory bodies, and industry stakeholders, facilitating the sharing and dissemination of emerging research findings and clinical insights.
Talent and Capacity Development: The three parties will explore cooperation opportunities to jointly promote training programs, workshops, and knowledge-sharing activities, aiming to enhance professional capabilities in clinical research in Hong Kong and the Greater Bay Area and cultivate a talent pipeline.
Professor Zhang Wenyong, CEO of the Greater Bay Area International Clinical Trials Institute, stated: "We are delighted to collaborate with Xihua Pharmaceutical under the 'One Institute, One Center' framework. The Institute will play the role of a liaison and facilitator, committed to supporting high-quality clinical research and promoting closer collaboration within the Greater Bay Area. With the signing of the memorandum of cooperation, we look forward to supporting the process of multi-center research conducted by Xihua Pharmaceutical, together with the Center, as an important link in continuously driving and strengthening Hong Kong's clinical trial ecosystem."
Dr. Li Yichong, Director of the Greater Bay Area International Clinical Trials Center, stated: "We are pleased to participate in this strategic cooperation with the Greater Bay Area International Clinical Trials Institute and Xihua Pharmaceutical. By combining the advantages of Hong Kong and the Greater Bay Area, this cooperation will drive the development of high-quality, multi-center clinical research and support innovative drug R&D. The Center will continue to strive to improve the clinical trial collaboration network and promote cross-border cooperation. We believe that this memorandum of cooperation will help enhance the competitiveness of clinical research in the Greater Bay Area and further consolidate its status as a hub for innovative biopharmaceuticals."
Dr. Lin Shunchao, Founder of Xihua Pharmaceutical, stated: "We are very happy to cooperate with the Greater Bay Area International Clinical Trials Institute and the Greater Bay Area International Clinical Trials Center. Xihua Pharmaceutical plans to conduct multiple international Phase III clinical trials in Hong Kong and the Greater Bay Area, leveraging Hong Kong to further exert the global advantages of China's clinical research ecosystem. Hong Kong possesses world-class medical infrastructure, rigorous data standards, and the unique advantage of being a 'super connector' between mainland China and global markets, making it an attractive location for conducting international clinical research. The coordination support provided by the 'One Institute, One Center' offers crucial assistance to us as a local startup pharmaceutical company."
This memorandum highlights the joint commitment of the three parties to consolidating Hong Kong's role as a regional clinical research hub and a portal for multi-regional clinical trials. The three parties will continue to explore cooperation opportunities under this framework, with specific projects to be implemented at an appropriate time.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
